



Neurodegenerative Diseases

- Licensing strategy for a company entering Alzheimer's and Parkinson's markets
- Valuation models for multiple novel product concepts in Parkinson's disease
- Market assessment across neurodegenerative diseases to guide market entry
- Clinical trial strategy for Alzheimer's imaging agent
- Commercialization strategy and launch plan for respiratory support device in ALS
- Development of a road map to expand a disease foundation's relationship with commercial partners
- Strategy for advancing multidisciplinary Parkinson's care at a network of medical centers



Pain and Migraine

- Clinical, scientific, and competitive analysis of ion channel modulators for use in chronic pain
- Development and co-positioning strategy for neuropathic pain franchise
- Clinical development and market adoption strategy for a new pain product
- Acquisition diligence of anti-abuse formulation for a novel opioid
- Commercial assessment of a controlled opioid delivery platform
- Strategic planning for a pain management device franchise
- Commercialization strategy for inhaled acute migraine therapy



Multiple Sclerosis

- Identification and prioritization of strategic initiatives for global neuro-immunology franchise
- Market assessment of RNAi-based technology for immune indications
- Elucidation of neurologist and patient unmet needs through clinic visits and on-site interviews
- Development costs and revenue projections for prognostic and predictive biomarkers
- US and EU commercialization strategy for biosimilar interferon
- Launch plan and post-marketing trial design for a new injectable therapy
- Portfolio prioritization for an MRI imaging company



Psychiatric Illnesses

- Impact of efficacy and side effects on revenue projections for generalized anxiety disorder drug
- Transaction diligence for the acquisition of an antidepressant franchise
- Revenue implications of increasing price in a highly competitive therapy class
- Strategy to increase CNS exposure through licensing and/or acquisition
- Forecast model utilizing detailed treatment algorithms in depression and related conditions
- Prioritization of indications for a novel, sustained-release drug formulation
- Evaluation of trends in sales and marketing costs